Drugs / Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine
Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine
also known as
MenACWY-CRM
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04006457 | Jul 2019 → Jun 2024 | alopecia areata | Pfizer | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04006457 ↗ |
| Known as | MenACWY-CRM | “This sub-study of a phase 3 study evaluated primary immune responses to the meningococcal groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate (MenACWY-CRM)...” PMID 41579233 ↗ Jan 2026 |
| Modality | Vaccine | “the meningococcal groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate (MenACWY-CRM) vaccine” PMID 41579233 ↗ Jan 2026 |